纪泛扑，男，1979年5月出生，医学博士，主任医师，博士生导师，美国斯坦福大学访问学者，AASLD会员，陕西青年科技奖获得者，肝胆相照基金会肝病营养研究2021年度先进个人，西安交通大学医学部国家级后备人才。现任西安交通大学第二附属医院学科建设办公室主任；陕西省感染性疾病临床医学研究中心副主任；教育部学位与研究生教育评估专家；陕西省性学会青年专家委员会副主任委员，陕西省传染病与寄生虫病学会青年委员，陕西省肝病学会自免肝学组委员，西安市感染症学会常务委员，西安市肝病学会委员；World Journal of Hepatology杂志编委，《中华实验与临床感染病杂志》编委，Journal of Clinical and Translational Hepatology 学术编辑和青年编委、《中国肝脏病杂志》青年编委，Clinical Gastroenterology and Hepatology、Alimentary Pharmacology and Therapeutics、Liver International、Journal of Viral Hepatitis、BMC Infectious Diseases、Journal of Medical Virology、World Journal of Gastroenterology、《中华传染病杂志》、《临床肝胆病杂志》等杂志审稿人。主持国家自然科学基金2项、横向课题1项、省校级基金8项。主持获西安交通大学临床医疗技术一等奖1项，参与获得陕西省科技进步一等奖1项。以第一或通信作者在J Hepatol、Hepatology、Chem Eng J、JAMA Netw Open、Aliment Pharmacol Ther、Clin Infect Dis、Theranostics、Stem Cells Transl Med、Stem Cell Res Ther、J Gastroenterol Hepatol、Infect Dis Poverty、J Clin Viral、J Med Virol等国际杂志发表SCI论文近40余篇。2018年在华盛顿DDW大会报告1次，2022、2020、2019、2018、2016在APASL大会/分会报告8次, 2018,2021全国感染病年会分会口头报告2次。
邮箱：jifanpu1979@163.com；infection@xjtu.edu.cn;
电话：15319435860
研究方向：
1. 肝细胞癌及消化道肿瘤与临床大数据
2. 肝纤维化、肝硬化发病机制与阻断治疗
3. 急慢性传染病与公共卫生管理
一、 教育经历：
2016/11-2017/11， 斯坦福大学医学中心，访问学者
2011/09–2015/06， 西安交通大学医学院，博士学位
2003/09–2006/07， 西安交通大学医学院 硕士学位
1997/09–2002/07， 西安交通大学医学院 学士学位
二、 科研与学术工作经历:
2022/01-至今， 西安交通大学第二附属医院感染科， 主任医师
2016/01-2021/12，西安交通大学第二附属医院感染科， 副主任医师
2009/12-2015/12，西安交通大学第二附属医院感染科， 主治医师
2006/07-2009/11，西安交通大学第二附属医院感染科， 住院医师
三、近5年主持校级以上科研项目情况
1.项目名称：靶向ITSN1超分子核酸恢复VEGF调节的LSEC分化治疗肝纤维化的应用基础研究
项目编号：82170626
经费来源：国家自然科学基金面上项目，55万
起止年月：2022.1-2025.12
2.项目名称：靶向肝窦内皮细胞防御素递送系统的构建及其抗纤维化作用研究
项目编号：2021SF-228
经费来源：陕西省重点研发计划，5万
起止年月：2021.1-2022.12
3.项目名称：新型冠状病毒肺炎重症化预测指标及间充质干细胞干预治疗新策略与机制探讨
项目编号：No.xzy032020040
经费来源：中央高校基本科研业务费新冠病毒应急科研项目，30万
起止年月：2020/02-2021/01
4.项目名称：西安交通大学医学部国家级后备人才（菁英计划）
项目编号：No.XJTURC201905
经费来源：西安交通大学医学部，50万
起止年月：2019.7-2022.06
5.项目名称：妊娠合并HTNV感染对孕妇和胎儿预后的影响
项目编号：No.xzy012019107
经费来源：中央高校基本科研业务费，12万
起止年月：2019.1-2021.12
6.项目名称：Real-world Evidence from the Asia Liver Consortium for HCV
项目编号：733559
经费来源：Stanford University and Gilead Sciences, Inc，2.75万美元
起止年月：2018.8.1-2022.4.31
7.项目名称：丙型肝炎肝硬化脾亢脾抑制T细胞功能诱导机体免疫耐受
项目编号：2017JM8092
经费来源：陕西省自然科学基金（面上项目），3万
起止年月：2017.1-2018.12
8.项目名称：脾切除改善丙型肝炎失代偿期肝硬化抗病毒应答的免疫机制研究
项目编号：81300322
经费来源：国家自然科学基金青年项目，23万
起止年月：2014.1-2016.12
四、 近5年以第一或通讯作者发表论文
1. Ji FP, Nguyen MH. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy. Lancet Oncol. 2022 Jul 4:S1470-2045(22)00383-7.
2. Yeo YH, He X, Ting PS, Zu J, Almario CV, Spiegel BMR, Ji FP*. Evaluation of Trends in Alcohol Use Disorder-Related Mortality in the US Before and During the COVID-19 Pandemic. JAMA Netw Open. 2022;5(5):e2210259.
3. Li J, Jiang N, Zeng QL, Zhang Y, He X, Chu Y, Jin W, Liu Y, Shi W, Yang M, He W, Han Q, Ma L, Xu Y, Guo Y, Zhang L, Ji FP*. The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection. Infect Drug Resist. 2022;15:2115-2125.
4. Li M, Zu J*, Zhang Y, Ma L, Shen M, Li Z, Ji FP*. COVID-19 epidemic in New York City: development of an age group-specific mathematical model to predict the outcome of various vaccination strategies. Virol J. 2022;19(1):43.
5. Xinxing Tantai,# Yi Liu,# Yee Hui Yeo,* Michael Praktiknjo, Ezequiel Mauro, Yuhei Hamaguchi, Cornelius Engelmann, Peng Zhang, Jae Yoon Jeong, Jeroen Laurens Ad van Vugt, Huijuan Xiao, Huan Deng, Xu Gao, Qing Ye, Jiayuan Zhang, Longbao Yang, Yaqin Cai, Yixin Liu, Na Liu, Zongfang Li, Tao Han, Toshimi Kaido, Joo Hyun Sohn, Christian Strassburg, Thomas Berg, Jonel Trebicka, Yao-Chun Hsu, Jan Nicolaas Maria IJzermans, Jinhai Wang,* Grace L. Su, Fanpu Ji,* Mindie H. Nguyen. Effect of sarcopenia on survival of patients with cirrhosis: A meta-analysis.J Hepatol. 2022;76(3):588-599.
6. Na Huang,# Rui zhou,# Haiyuan Chen, Shu Zhang, Jun Li, Wei Wei, Jin Sun, Song Ren, Baohua Li, Hong Deng, Jun Yang, Fanpu Ji*, Zongfang Li*. Splenic CD4+ and CD8+ T cells highly expressed PD-1 and Tim-3 in cirrhotic patients with HCV infection and portal hypertension.Int J Immunopathol Pharmacol. 2021;35:20587384211061051.
7. Yunyu Zhao#, Zhipeng Yan#, Ying Liu, Yue Zhang, Jie Shi, Jingtao Li*, Fanpu Ji*. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Stem Cell Res Ther. 2021;12(1):470.
8. Miaolei Li, Jian Zu*, Zongfang Li, Mingwang Shen, Yan Li, Fanpu Ji*. How to Reduce the Transmission Risk of COVID-19 More Effectively in New York City: An Age-Structured Model Study. Front Med. 2021; 8: 641205.
9. Fanpu Ji, Ting Li, Mindie H Nguyen*. Improved survival and high sustained virologic response with DAA therapy in patients with HCV-related HCC: A call for expanded use. J Gastroenterol Hepatol. 2021;36(6):1721-1722.
10. Jin Yan#,*, Wangxiao He#,*, Xiao Li#, Weiming You, Xiaojing Liu, Shumei Lin, Jianghao Chen, Yunyu Zhao, Yanmin Zhang*, Fanpu Ji*. Carnosic acid-induced co-self-assembly of metal-peptide complexs into nanocluster-based frameworks with tumor-specific accumulation for augmented immnuotherapy. Chem Eng J. 2021; 416:129141.
11. Qing-Lei Zeng#, Zu-Jiang Yu#, Fanpu Ji#, Guang-Ming Li, Guo-Fan Zhang, Jiang-Hai Xu, Zhi-Min Chen, Guang-Lin Cui, Wei Li, Da-Wei Zhang, Juan Li, Jun Lv, Zhi-Qin Li, Hong-Xia Liang, Chang-Yu Sun, Ya-Jie Pan, Yan-Min Liu, Fu-Sheng Wang. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: A multicenter, prospective, observational study. Clin Infect Dis. 2021;73(9): e3324- e3332.
12. Fanpu Ji, Jie Li, Li Liu, Jing Liang, Xiaozhong Wang, Junping Liu, Dachuan Cai, Rui Huang, Jiajie Zhang, Qi Wang, Yuemin Nan, Junyi Li, Qing Ye, Mingyuan Zhang, Qiang Xu, Feng Guo, Changqing Zhao, Lingdi Liu, Caini He, Yu Li, Wenjun Wang, Leslie Y. Kam, Sally Tran, Mayumi Maeda, Akiko Mizuta, Zongfang Li, Shuangsuo Dang, Wanhua Ren, Qiang Zhu, Ramsey Cheung, Junqi Niu, Wen Xie, Hongying Pan, Hong Ren, Chao Wu, Jia Shang, Fengmei Wang, Mindie H. Nguyen*. High HCV cure rates with approved interferon‐free direct acting antivirals among diverse Mainland Chinese patients including genotypes 3a and 3b. J Gastroenterol Hepatol, 2021;36(3):767-774.
13. Jian Zu, Miao-Lei Li, Zong-Fang Li, Ming-Wang Shen, Yan-Ni Xiao, Fanpu Ji*. Transmission patterns of COVID-19 in the mainland of China and the efficacy of different control strategies: a data- and model-driven study. Infect Dis Poverty. 2020;9(1):83.
14. Zeng QL*#, Li GM#, Ji FP#, Ma SH#, Zhang GF#, Xu JH#, Lin WB#, Xu GH#, Zhang GQ, Li GT, Cui GL, Liu N, Zeng FJ, Ai ZG, Xu GF, Liu N, Liang J, Zhang MM, Li C, Zhang ZH, Wang ZS, Li Z, Yu ZJ*. Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study. Transbound Emerg Dis. 2020;67(6):2971-2982.
15. Ji FP, Li LY, Li ZF, Jin Y*, Liu WJ*. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med. 2020; 9(7):813-814.
16. Liu Yuanyuan, Li Yongqin, Wang Qiaoxia, Fu Jianjun, Ji Fanpu*. Sporadic human cutaneous anthrax outbreak in Shaanxi Province, China: report of two cases from 2018. Braz J Infect Dis. 2020;24(1):81-84.
17. Ji Fanpu,# Yeo Yee Hui,# Wei Mike Tzuhen, Ogawa Eiichi, Enomoto Masaru, Lee Dong Hyun, Iio Etsuko, Lubel John, Wang Wenjun, Wei Bin, Ide Tatsuya, Preda Carmen Monica, Conti Fabio, Minami Tatsuya, Bielen Rob, Sezaki Hitomi, Barone Michele, Kolly Philippe, Chu Po-sung, Virlogeux Victor, Eurich Dennis, Henry Linda, Bass Michelle B, Kanai Takanori, Dang Shuangsuo, Li Zongfang, Dufour Jean-François, Zoulim Fabien, Andreone Pietro, Cheung Ramsey, Tanaka Yasuhito, Furusyo Norihiro, Toyoda Hidenori, Tamori Akihiro, Nguyen Mindie*. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. J Hepatol. 2019;71(3):473-485.
18. Ji Fanpu, Yeo Yee Hui, He Caini, Li Jie, Gao Xuesong, Li Zongfang, Henry Linda, Nguyen Mindie. Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment. J Hepatol. 2019;70(1):209-211.
19. Ji Fanpu,# Wei Bin,# Yeo Yee Hui, Ogawa Eiichi, Zou Biyao, Stave Christopher D, Li Zongfang, Dang Shuangsuo, Furusyo Norihiro, Cheung Ramsey C, Nguyen Mindie H. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther. 2018;47(5):550-562. (IF 7.731)
20. Ji Fanpu, Yeo Yee Hui, Wei Mike Tzuhen, Wei Bin, Dang Shuangsuo, Li Zongfang, Nguyen Mindie H. Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter? Hepatology. 2018; 67(3):1180-1182.
21. Wei Bin,# Ji Fanpu,# Yeo Yee Hui, Ogawa Eiichi, Zou Biyao, Stave Christopher D, Dang Shuangsuo, Li Zongfang, Furusyo Norihiro, Cheung Ramsey, Nguyen Mindie. Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2018; 5(1):e000207.
22. Ji Fanpu, Zhou Rui, Wang Wenjun, Bai Dan, He Caini, Cai Zhifang, Shen Yuan, Wang Shengbang, Deng Hong, Li Zongfang. High post-treatment α-fetoprotein levels and aspartate aminotransferase-to-platelet ratio index predict hepatocellular carcinoma in hepatitis C virus decompensated cirrhotic patients with sustained virological response after antiviral therapy. J Interferon Cytokine Res. 2017; 37(8): 362-368.
23. Ji Fanpu, Wang Wenjun, Dang Shuangsuo, Wang Shengbang, Li Burong, Bai Dan, Zhao Wenxue, Deng Hong, Tian Changyin, Li Zongfang. Outcomes after sofosbuvir containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real world study. Infect Agent Cancer. 2017;12:48.
24. 贺彩妮#，杜虹#，牛迎花#，赵文轩#，高宁，李慎，黄娜，赵蕴玉，李孝锋，张悦，李梅，邓欢，刘海玲，赵英仁*，连建奇*，纪泛扑*.妊娠合并肾综合征出血热患者临床特征的多中心研究.中华传染病杂志，2021,39(12):746-752.
25. 徐强#，张伟#，马玉秀#，贺彩妮#，张立婷，依力哈木·阿不力提甫，李彧，王楠，王宏利，赵蕴玉，高旭，高培根，粟兴洋，李慎，刘媛媛，郭峰，陈章乾，刘海玲，高晓琴，付建军，于国英，王晓忠，王九萍*，张永萍*，纪泛扑*. 12周索磷布韦/维帕他韦方案治疗西北地区慢性丙型肝炎患者：一项真实世界多中心临床研究.中华肝脏病杂志, 2021,29(11):1046-1052.
26. 高旭, 纪泛扑*. 直接抗病毒药物时代丙型肝炎病毒相关肝细胞癌的诊治对策. 中华肝脏病杂志, 2020,28 (10): 827-830.
27. 赵蕴玉，贺彩妮，高培根，刘莹，姚雷清，高蓉，刘佳姝，魏伏，李慎，朱龙飞，李政霄，纪泛扑*. 直接抗病毒药物治疗六例丙型肝炎病毒相关性皮肤损害患者的回顾性研究 中华实验和临床感染病杂志，2020,14(6):507-512.
28. 贺彩妮#，李彧#，葛蘅，魏伏，马晓桃，王文俊，高宁，段朝阳，纪泛扑*. 基于索磷布韦方案治疗HCV相关性肾小球肾炎的效果和安全性. 临床肝胆病杂志, 2019, 35(8): 1714-1718.
